MBDB

MBDB (3,4-methylenedioxy-N-methylbutan-1-amine) is a psychoactive synthetic amphetamine of the methylenedioxyphenyl family. It is an entactogen closely related to MDMA and has appeared on the market as a designer drug in various contexts, sometimes sold under street names such as Eden. It is typically used for mood-altering and empathy-promoting effects.

Pharmacology and effects: MBDB releases serotonin and, to a lesser extent, dopamine and norepinephrine, contributing to emotional openness, empathy, mild euphoria, and heightened sensory perception. Physical effects can include increased heart rate, pupil dilation, jaw clenching, and sweating. Onset is usually within one to two hours, with effects lasting several hours. Relative to MDMA, MBDB is commonly described as less stimulating and sometimes less intense, though potency and duration vary with dose and purity.

Safety and risks: Illicit MBDB products may be adulterated with other substances, and potency can be unpredictable. Risks overlap with other MDxx compounds and include hyperthermia, dehydration, hyponatremia, nausea, and anxiety. Higher doses or concurrent use with other serotonergic drugs raise the risk of serotonin syndrome. Repeated use has been associated with mood disturbances and cognitive effects in some users, though data are limited compared with MDMA.

Legal status and use: MBDB has appeared as a designer drug in club and party settings. Legal status varies by country; in many jurisdictions it is controlled as a prohibited substance. Because clinical data are limited, MBDB is not approved for medical use.